PHIA Koninklijke Philips N.V.

Philips announces new imaging and workflow enhancements for KODEX-EPD cardiac imaging and mapping system to treat heart rhythm disorders

Philips announces new imaging and workflow enhancements for KODEX-EPD cardiac imaging and mapping system to treat heart rhythm disorders

August 26, 2020

  • New release combines faster, higher resolution imaging for Medtronic cryoablation procedures
  • KODEX-EPD system now installed at 40 sites worldwide with over 1500 patients treated

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new imaging and workflow enhancements for its novel KODEX-EPD cardiac imaging and mapping system. The system is now being used to treat patients with Atrial Fibrillation (AF), a common heart rhythm disorder, at 40 sites worldwide with over 1500 patients treated. The latest release includes improvements in imaging and mapping performance, as well as enhanced features to support cryoablation procedures.

Unlike traditional methods to image the heart during AF procedures such as CT and X-ray fluoroscopy, the KODEX-EPD system uses a combination of sensors attached to the body and catheters inside the heart to image the anatomy and properties of the heart, using innovative dielectric sensing technology. As a result, electrophysiologists can create detailed 3D views of the heart of a patient in as little as three minutes and navigate to the target location more easily and efficiently, with the required precision and without using radiation.

“The new release of the KODEX-EPD system represents a significant step forward in terms of image quality and workflow efficiency for AF procedures, as we continue to work towards our longer term goal of providing real-time therapy assessment,” said Marlou Janssen, General Manager Philips EPD Solutions. “By partnering with Medtronic and developing unique capabilities for cryoablation, we can give more physicians access to this truly innovative cardiac imaging and mapping system, and contribute to delivering efficient workflows with Medtronic’s best-in-class cryoablation therapy.”

Advances in the new release include faster, high-resolution imaging, improvements in mapping functionality and point density, as well as new visualization options such as ‘multi-chamber’ view to help understand the relative positions of adjacent chambers and ‘glass view’, which provides physicians with an improved perception of 3D catheter location and orientation within the heart. For cryoablation procedures, the KODEX-EPD system offers enhanced Occlusion assessment functionality with high accuracy and a simplified workflow [1].

“Using the KODEX-EPD imaging system’s ability to provide high resolution imaging,  revealing specific pulmonary vein morphologies, has allowed me to personalize my ablation approach in Medtronic cryoballoon procedures,” said Marcin Kowalski MD, Director of Electrophysiology at , US. “Using the two innovative technologies together has significant benefits for our patients.”

                              

“Combining the short procedure times of cryoablation with the real-time imaging capabilities of the KODEX-EPD system, we have been able to further improve our efficient lab workflow” said Professor Lukas Dekker, Electrophysiologist at in Eindhoven, the Netherlands. “Moreover, fluoroless imaging with the KODEX-EPD system may reduce the dependency on fluoroscopy and pre-procedural CTs and thus help to reduce X-ray exposure to patients and staff, which is important to us.”

The KODEX-EPD cardiac imaging and mapping system is commercially available in the US, Europe, and China. It is part of Philips’ unique portfolio of systems, smart devices, software and services in image-guided therapy, which combine to provide healthcare providers with sophisticated, procedure-oriented solutions. More information is available at .

[1] While using KODEX-EPD occlusion functionality, physicians should always refer to the applicable cryoballoon technical manual, published literature, and exercise their discretion to guide confirmation of pulmonary vein occlusion.

For further information, please contact:

Steve Klink

Philips Group Press Office

Tel:

Email:

Fabienne van der Feer

Philips Image Guided Therapy

Tel:

Email:

 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



 

Attachments

EN
26/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips Foundation 2024 Annual Report: expanding access to quality hea...

Philips Foundation 2024 Annual Report: expanding access to quality healthcare for 46.5 million people In 2024, Philips Foundation initiated 22 new projects and 5 new impact investments expanding its impact and reach in innovative healthcare delivery to India and South AmericaCelebrating a decade of impact with strong progress towards the Foundation’s 2030 goal to improve access to healthcare for 100 million people in underserved communities a yearThe combined impact of longstanding strategic collaborations and new innovative partnerships with healthcare ventures affirm the Foundation’s appr...

 PRESS RELEASE

Philips announces exchange ratio for 2024 dividend

Philips announces exchange ratio for 2024 dividend June 5, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been g...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ageas: Reinsurance partnership with TRIGLAV, taking QS on Italian motor direct insurance Belgian Telecoms: Digi introduces a new mobile subscription at €3. Kinepolis: Box office in US/Canada up 76% YoY while France visitors were down 25%. NN Group & ASR: Dutch coalition collapse not affecting Dutch Pension Reform. SBM Offshore: Farewell Aseng after 13.5 years of service. Events Calendar

Marc Hesselink ... (+3)
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Benelux Tech update/Our favourites: ASM, Barco, BESI, RELX

We refresh our Benelux Tech coverage following the 1Q25 reporting season. In this note we downgrade Just Eat Takeaway from Buy to HOLD as we believe the takeover offer is fair. Most companies reported largely in line results and, across the board we make relatively modest changes to our estimates. Our highest conviction longs in the Benelux Tech universe are ASM International, Barco, BE Semiconductor Industries and RELX. Our biggest increase in target price is for Prosus which saw strong perfor...

 PRESS RELEASE

Philips to repurchase up to 6 million shares to cover long-term incent...

Philips to repurchase up to 6 million shares to cover long-term incentive plans June 4, 2025  Amsterdam, the Netherlands –  (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 125 million. The repurchases will be executed through one or more individual forward transactions, to be entered into in the course of the second and third quarter of 2025, in accordance with the Market Abuse Regulation...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch